$BAVA (+3,76%) The German-Danish vaccine specialist Bavarian Nordic clearly exceeded market expectations with its figures for the second quarter. The company easily exceeded estimates for both turnover and profit. Bavarian Nordic then also specified its forecast for the current year.

With sales of 1.43 billion Danish kroner (equivalent to 191.2 million euros) in the second quarter, the vaccine manufacturer clearly beat the estimate of 1.18 billion kroner. EBITDA amounted to 420 million kroner (56.3 million euros); analysts had only estimated just under 203 million kroner.

Bavarian Nordic now expects sales of around 5.30 billion kronor and EBITDA of 1.35 billion kronor for 2024. Both figures are at the upper end of the previously defined target range.